Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 2/20 | 0.45 |
| ▸ | RUNX1 | Q01196 | 6/20 | 0.44 |
| ▸ | CBFB | Q13951 | 3/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4036018 | 0.82 | KIT (0.49) | PDPK1RUNX1CBFBFGFR1ERBB2 | |
| SCHEMBL4039633 | 0.80 | FGFR1 (0.41) | PDPK1FGFR1FLT3CLK4CDK1 | |
| SCHEMBL4043185 | 0.79 | PDPK1 (0.67) | PDPK1FGFR1FLT3CLK4CDK1 | |
| SCHEMBL4034563 | 0.78 | CDK1 (0.66) | RUNX1TRPA1ERBB2CDK1 | |
| SCHEMBL4037154 | 0.78 | PDPK1 (0.51) | PDPK1RUNX1CBFBFGFR1FLT3 | |
| SCHEMBL4037113 | 0.73 | RET (0.62) | PDPK1FGFR1FLT3ERBB2CDK1 | |
| SCHEMBL5951426 | 0.71 | CBFB (0.47) | RUNX1CBFBTRPA1TRPV1SCN5A | |
| SCHEMBL7066940 | 0.70 | RUNX1 (0.43) | RUNX1CBFBTRPA1TRPV1SCN5A | |
| SCHEMBL179102 | 0.70 | CBFB (0.82) | RUNX1CBFBTRPA1TRPV1 | |
| SCHEMBL17525964 | 0.70 | RUNX1 (0.83) | RUNX1CBFBTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541367-B2 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-06-02 | — | — | US | disclosed |
| US-20090048249-A1 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-02-19 | — | — | US | disclosed |
| WO-2006130673-A1 | 3-BENZOIMIDAZOLYL-PYRAZOLOPYRIDINES USEFUL IN TREATING KINASE DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048249-A1 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | PRKDC, PRKACA, ABL1 | PDPK1 90/4885RUNX1 1458/4885CBFB 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.